vs
CollPlant Biotechnologies Ltd（CLGN）与Envoy Medical, Inc.（COCH）财务数据对比。点击上方公司名可切换其他公司
CollPlant Biotechnologies Ltd的季度营收约是Envoy Medical, Inc.的2.4倍（$179.0K vs $75.0K）。CollPlant Biotechnologies Ltd净利率更高（-1869.8% vs -8781.3%，领先6911.5%）。Envoy Medical, Inc.同比增速更快（78.6% vs -28.1%）
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
Envoy Medical是一家专注于植入式听力解决方案研发和商业化的医疗科技企业，核心产品为全植入式中耳听力设备，主要服务于使用常规外置助听器效果不佳的感音神经性听力损失患者，市场覆盖北美、欧洲等地区。
CLGN vs COCH — 直观对比
营收规模更大
CLGN
是对方的2.4倍
$75.0K
营收增速更快
COCH
高出106.7%
-28.1%
净利率更高
CLGN
高出6911.5%
-8781.3%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $179.0K | $75.0K |
| 净利润 | $-3.3M | $-6.6M |
| 毛利率 | -3.9% | -181.3% |
| 营业利润率 | -1775.4% | -8513.3% |
| 净利率 | -1869.8% | -8781.3% |
| 营收同比 | -28.1% | 78.6% |
| 净利润同比 | 20.5% | -42.6% |
| 每股收益（稀释后） | $0.28 | $-0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLGNCOCH
| Q4 25 | — | $75.0K | ||
| Q3 25 | — | $42.0K | ||
| Q2 25 | $179.0K | $78.0K | ||
| Q1 25 | — | $46.0K | ||
| Q4 24 | — | $42.0K | ||
| Q3 24 | — | $56.0K | ||
| Q2 24 | $249.0K | $68.0K | ||
| Q1 24 | — | $59.0K |
净利润CLGNCOCH
| Q4 25 | — | $-6.6M | ||
| Q3 25 | — | $-6.5M | ||
| Q2 25 | $-3.3M | $-5.7M | ||
| Q1 25 | — | $-5.0M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | — | $-6.0M | ||
| Q2 24 | $-4.2M | $-3.9M | ||
| Q1 24 | — | $-6.3M |
毛利率CLGNCOCH
| Q4 25 | — | -181.3% | ||
| Q3 25 | — | -383.3% | ||
| Q2 25 | -3.9% | -200.0% | ||
| Q1 25 | — | -391.3% | ||
| Q4 24 | — | -273.8% | ||
| Q3 24 | — | -233.9% | ||
| Q2 24 | -115.3% | -260.3% | ||
| Q1 24 | — | -159.3% |
营业利润率CLGNCOCH
| Q4 25 | — | -8513.3% | ||
| Q3 25 | — | -13590.5% | ||
| Q2 25 | -1775.4% | -6500.0% | ||
| Q1 25 | — | -11102.2% | ||
| Q4 24 | — | -10828.6% | ||
| Q3 24 | — | -8878.6% | ||
| Q2 24 | -1769.5% | -7135.3% | ||
| Q1 24 | — | -8278.0% |
净利率CLGNCOCH
| Q4 25 | — | -8781.3% | ||
| Q3 25 | — | -15433.3% | ||
| Q2 25 | -1869.8% | -7294.9% | ||
| Q1 25 | — | -10865.2% | ||
| Q4 24 | — | -10995.2% | ||
| Q3 24 | — | -10642.9% | ||
| Q2 24 | -1690.8% | -5804.4% | ||
| Q1 24 | — | -10627.1% |
每股收益（稀释后）CLGNCOCH
| Q4 25 | — | $-0.27 | ||
| Q3 25 | — | $-0.35 | ||
| Q2 25 | $0.28 | $-0.32 | ||
| Q1 25 | — | $-0.29 | ||
| Q4 24 | — | $-0.40 | ||
| Q3 24 | — | $-0.39 | ||
| Q2 24 | $0.37 | $-0.29 | ||
| Q1 24 | — | $-0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.5M | $-12.2M |
| 总资产 | $17.4M | $8.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLGNCOCH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $11.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | — | — |
股东权益CLGNCOCH
| Q4 25 | — | $-12.2M | ||
| Q3 25 | — | $-7.7M | ||
| Q2 25 | $12.5M | $-29.9M | ||
| Q1 25 | — | $-24.2M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-18.5M | ||
| Q2 24 | $20.7M | $-12.4M | ||
| Q1 24 | — | $-7.4M |
总资产CLGNCOCH
| Q4 25 | — | $8.6M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $17.4M | $9.9M | ||
| Q1 25 | — | $10.4M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | $26.6M | $6.7M | ||
| Q1 24 | — | $8.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.9M |
| 自由现金流率自由现金流/营收 | — | -7809.3% |
| 资本支出强度资本支出/营收 | — | 229.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLGNCOCH
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-2.6M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | — | $-5.6M |
自由现金流CLGNCOCH
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-3.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-5.7M |
自由现金流率CLGNCOCH
| Q4 25 | — | -7809.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -5719.2% | ||
| Q1 25 | — | -8110.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -6750.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9657.6% |
资本支出强度CLGNCOCH
| Q4 25 | — | 229.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 13.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2066.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 184.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
